Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application

被引:27
作者
Quintas-Cardama, Alfonso [1 ]
Yeh, Raymond K. [1 ]
Hollyman, Daniel [2 ]
Stefanski, Jolanta [2 ]
Taylor, Clare [2 ]
Nikhamin, Yan [1 ]
Imperato, Gavin [1 ]
Sadelain, Michel [1 ,3 ]
Riviere, Isabelle [1 ,3 ]
Brentjens, Renier J. [1 ]
机构
[1] Dept Med, New York, NY 10021 USA
[2] Gene Transfer & Somat Cell Engn Lab, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA
关键词
D O I
10.1089/hum.2007.088
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The ability to genetically modify human T cells to target tumor antigens through retroviral gene transfer constitutes a potentially powerful approach to cancer immunotherapy. However, low transduction efficiencies may hamper the efficacy of such therapeutic strategies in the clinical setting. Most commonly, gammaretroviral gene transfer into T cells is conducted through spinoculation, that is, centrifugation of retroviral particles and T cells on RetroNectin-coated non-tissue culture vessels. Here we present data investigating the impact of temperature, speed, and frequency of spinoculation on T cell transduction efficiencies. We found that all three variables independently impacted gene transfer, with increasing temperature, speed, and frequency of spinoculation all enhancing the transduction of T cells. These improved conditions were additive, with the greatest proportion of transduced T cells being generated at the highest tested temperature and speed, after daily spinoculation for 2 to 3 days. Under these conditions, enhanced gene transfer was observed in T cells derived from healthy donors, using research-grade vector stocks. Whereas both RetroNectin and spinoculation were critical to optimal gene transduction, preloading of gammaretroviral particles before spinoculation did not enhance gene transfer. Significantly, application of these enhanced transduction conditions to T cells derived from previously treated patients with chronic lymphocytic leukemia allowed for adequate gene transfer under both small-scale and large-scale clinically applicable conditions using either preclinical or current Good Manufacturing Practice-grade gammaretroviral vector stocks.
引用
收藏
页码:1253 / 1260
页数:8
相关论文
共 25 条
[1]   Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements [J].
Ayuk, FA ;
Li, Z ;
Kühlcke, K ;
Lindemann, C ;
Schade, UM ;
Eckert, HG ;
Zander, AR ;
Fehse, B .
GENE THERAPY, 1999, 6 (10) :1788-1792
[2]   T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS [J].
BLAESE, RM ;
CULVER, KW ;
MILLER, AD ;
CARTER, CS ;
FLEISHER, T ;
CLERICI, M ;
SHEARER, G ;
CHANG, L ;
CHIANG, YW ;
TOLSTOSHEV, P ;
GREENBLATT, JJ ;
ROSENBERG, SA ;
KLEIN, H ;
BERGER, M ;
MULLEN, CA ;
RAMSEY, WJ ;
MUUL, L ;
MORGAN, RA ;
ANDERSON, WF .
SCIENCE, 1995, 270 (5235) :475-480
[3]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[4]   GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS [J].
BORDIGNON, C ;
NOTARANGELO, LD ;
NOBILI, N ;
FERRARI, G ;
CASORATI, G ;
PANINA, P ;
MAZZOLARI, E ;
MAGGIONI, D ;
ROSSI, C ;
SERVIDA, P ;
UGAZIO, AG ;
MAVILIO, F .
SCIENCE, 1995, 270 (5235) :470-475
[5]   Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts [J].
Brentjens, Renier J. ;
Santos, Elmer ;
Nikhamin, Yan ;
Yeh, Raymond ;
Matsushita, Maiko ;
La Perle, Krista ;
Quintas-Cardama, Alfonso ;
Larson, Steven M. ;
Sadelain, Michel .
CLINICAL CANCER RESEARCH, 2007, 13 (18) :5426-5435
[6]   Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].
Brentjens, RJ ;
Latouche, JB ;
Santos, E ;
Marti, F ;
Gong, MC ;
Lyddane, C ;
King, PD ;
Larson, S ;
Weiss, M ;
Rivière, I ;
Sadelain, M .
NATURE MEDICINE, 2003, 9 (03) :279-286
[7]   HIGH-EFFICIENCY RETROVIRAL-MEDIATED GENE-TRANSFER INTO HUMAN AND NONHUMAN PRIMATE PERIPHERAL-BLOOD LYMPHOCYTES [J].
BUNNELL, BA ;
MUUL, LM ;
DONAHUE, RE ;
BLAESE, RM ;
MORGAN, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7739-7743
[8]   LYMPHOCYTES AS CELLULAR VEHICLES FOR GENE-THERAPY IN MOUSE AND MAN [J].
CULVER, K ;
CORNETTA, K ;
MORGAN, R ;
MORECKI, S ;
AEBERSOLD, P ;
KASID, A ;
LOTZE, M ;
ROSENBERG, SA ;
ANDERSON, WF ;
BLAESE, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) :3155-3159
[9]   Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells [J].
Hanenberg, H ;
Xiao, XL ;
Dilloo, D ;
Hashino, K ;
Kato, I ;
Williams, DA .
NATURE MEDICINE, 1996, 2 (08) :876-882
[10]  
HWU P, 1993, J IMMUNOL, V150, P4104